005250.KS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 02:30):

Stats
Today's Volume	66 111.00
Average Volume	62 569.00
Market Cap	680.30B
EPS	KRW0 ( 2024-02-13 )
Next earnings date	( KRW0 ) 2024-05-12
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW12.69 (0.08%)

Volume Correlation

Long: -0.05 (neutral)

Short: -0.68 (moderate negative)

Signal:(31.93) Neutral

Green Cross Holdings Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Green Cross Holdings Correlation - Currency/Commodity

-0.33
( neutral )

-0.32
( neutral )

-0.05
( neutral )

-0.31
( neutral )

-0.41
( neutral )

0.12
( neutral )

Green Cross Holdings Financials

Annual	2023
Revenue:	KRW2 057.94B
Gross Profit:	KRW563.69B (27.39 %)
EPS:	KRW-1 192.38

Q4	2023
Revenue:	KRW541.57B
Gross Profit:	KRW125.59B (23.19 %)
EPS:	KRW-209.99

Q3	2023
Revenue:	KRW541.72B
Gross Profit:	KRW170.97B (31.56 %)
EPS:	KRW-185.62

Q2	2023
Revenue:	KRW536.34B
Gross Profit:	KRW167.81B (31.29 %)
EPS:	KRW-232.05

Financial Reports:

No articles found.

Green Cross Holdings

Green Cross Holdings Corporation operates as a biotechnology company. The company provides plasma derivatives, prescription drugs, over the counter drugs, and hunter syndrome drugs; and vaccines for hemorrhagic fever, varicella, hepatitis-B, and flu. It also researches and develops oncology, immunology, and cell therapy products; and offers recombinant protein treatment for hemophilia. The company has partnerships and collaborations with biotech companies and academia for development of new drugs and technologies. Green Cross Holdings was founded in 1967 and is headquartered in Yongin, South Korea.